|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent No. 7,459,428: Dexmethylphenidate Hydrochloride
U.S. Patent No. 7,459,428, titled "Stabilized Formulations of Dexmethylphenidate," issued on December 2, 2008, to Shire Pharmaceuticals Ireland Limited. This patent covers stabilized formulations of dexmethylphenidate hydrochloride. Dexmethylphenidate is the d-threo enantiomer of methylphenidate, a central nervous system stimulant prescribed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent's claims focus on specific crystalline forms and stabilized compositions of dexmethylphenidate hydrochloride, aiming to improve the drug product's shelf life and therapeutic performance.
What is the Primary Innovation Claimed in Patent No. 7,459,428?
The core innovation protected by U.S. Patent No. 7,459,428 lies in the identification and characterization of specific, stabilized crystalline forms of dexmethylphenidate hydrochloride, and formulations incorporating these forms. Prior art formulations often suffered from stability issues, leading to degradation of the active pharmaceutical ingredient (API) over time, impacting efficacy and safety. This patent addresses these limitations by claiming compositions that exhibit enhanced stability.
Specifically, the patent claims focus on:
- Specific Crystalline Forms: The patent details and claims specific crystalline forms of dexmethylphenidate hydrochloride, referred to as "Form A" and "Form B." These forms are characterized by distinct X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and infrared (IR) spectroscopy data. The claims assert that these specific crystalline forms are more stable compared to other potential polymorphic forms or amorphous forms of dexmethylphenidate hydrochloride.
- Stabilized Formulations: Beyond the API itself, the patent claims encompass pharmaceutical compositions that include these stabilized crystalline forms of dexmethylphenidate hydrochloride, along with various excipients. These formulations are designed to maintain the integrity of the API under defined storage conditions, preventing or minimizing degradation pathways. The stabilization is attributed to the inherent properties of the claimed crystalline forms and potentially the judicious selection of excipients and manufacturing processes.
What are the Key Crystalline Forms and Their Characterization Data?
Patent No. 7,459,428 defines and claims two primary crystalline forms of dexmethylphenidate hydrochloride: Form A and Form B. The patent provides specific analytical data to distinguish these forms.
Form A:
- X-Ray Powder Diffraction (XRPD): The patent describes Form A as exhibiting characteristic diffraction peaks at specific 2-theta angles. Key peaks are listed, for example, at approximately 7.4, 12.9, 14.8, 18.7, 20.7, and 23.4 degrees (±0.2 degrees). These distinctive peak positions define the unique lattice structure of Form A.
- Differential Scanning Calorimetry (DSC): Form A is characterized by a specific endothermic peak, typically around 105°C to 107°C, representing its melting point or solid-state transition.
- Infrared (IR) Spectroscopy: The patent also provides characteristic IR absorption bands for Form A, offering another method for identification and differentiation.
Form B:
- X-Ray Powder Diffraction (XRPD): Form B is differentiated by its unique XRPD pattern, with characteristic diffraction peaks at different 2-theta angles compared to Form A. Key peaks are provided, such as those at approximately 8.6, 14.1, 17.1, 19.8, 21.5, and 24.5 degrees (±0.2 degrees).
- Differential Scanning Calorimetry (DSC): Form B exhibits a distinct endothermic peak in its DSC profile, often around 125°C to 127°C, indicating a different thermal behavior from Form A.
- Infrared (IR) Spectroscopy: Characteristic IR absorption bands for Form B are also detailed in the patent, serving as a complementary identification tool.
The patent asserts that Form A and Form B possess improved stability profiles, which translates to longer shelf-life and more consistent therapeutic delivery of dexmethylphenidate hydrochloride.
What Specific Claims Does Patent No. 7,459,428 Protect?
U.S. Patent No. 7,459,428 contains multiple claims directed to the stabilized formulations and crystalline forms of dexmethylphenidate hydrochloride. The claims define the legal scope of the patent protection.
Representative Claims Include:
- Claim 1: A crystalline form of dexmethylphenidate hydrochloride designated as Form A, characterized by an X-ray powder diffraction pattern having characteristic peaks at approximately 7.4, 12.9, 14.8, 18.7, 20.7, and 23.4 degrees 2-theta (±0.2 degrees 2-theta). This is a compound-specific claim defining a particular polymorphic form.
- Claim 2: The crystalline form of dexmethylphenidate hydrochloride of claim 1, further characterized by a differential scanning calorimetry profile having an endotherm at about 105°C to 107°C. This claim narrows Claim 1 by adding a thermal characterization parameter.
- Claim 3: A crystalline form of dexmethylphenidate hydrochloride designated as Form B, characterized by an X-ray powder diffraction pattern having characteristic peaks at approximately 8.6, 14.1, 17.1, 19.8, 21.5, and 24.5 degrees 2-theta (±0.2 degrees 2-theta). This is another compound-specific claim for a different polymorphic form.
- Claim 4: The crystalline form of dexmethylphenidate hydrochloride of claim 3, further characterized by a differential scanning calorimetry profile having an endotherm at about 125°C to 127°C. This claim narrows Claim 3 by adding a thermal characterization parameter.
- Claim 5: A pharmaceutical composition comprising a crystalline form of dexmethylphenidate hydrochloride according to claim 1, and at least one pharmaceutically acceptable excipient. This claim broadens protection to include compositions containing Form A.
- Claim 6: A pharmaceutical composition comprising a crystalline form of dexmethylphenidate hydrochloride according to claim 3, and at least one pharmaceutically acceptable excipient. This claim broadens protection to include compositions containing Form B.
- Claim 7: A process for preparing a stabilized crystalline form of dexmethylphenidate hydrochloride, comprising: (a) dissolving dexmethylphenidate hydrochloride in a solvent system; (b) inducing crystallization of dexmethylphenidate hydrochloride from the solvent system to form a crystalline solid; and (c) isolating the crystalline solid. This claim focuses on a method for producing the claimed stabilized forms.
- Claim 8: A pharmaceutical composition comprising dexmethylphenidate hydrochloride, wherein the dexmethylphenidate hydrochloride is in a crystalline form that exhibits a weight loss of less than 0.5% by Karl Fischer titration when stored at 40°C and 75% relative humidity for 3 months. This claim defines stability based on a specific storage test and measurement, providing a functional claim.
- Claim 9: The pharmaceutical composition of claim 5, further comprising a binder, a diluent, a disintegrant, and a lubricant. This claim further specifies excipients for compositions containing Form A.
- Claim 10: The pharmaceutical composition of claim 8, wherein the crystalline form is Form A. This claim links the stability defined in Claim 8 to the specific Form A.
These claims, particularly those defining the specific crystalline forms (e.g., Claims 1 and 3) and the stabilized compositions (e.g., Claims 5, 6, and 8), are crucial for asserting patent infringement.
What is the Patent Term and Expiration Date for U.S. Patent No. 7,459,428?
U.S. Patent No. 7,459,428 was filed on January 27, 2006, as a continuation-in-part application of U.S. Patent Application No. 10/678,247, filed on October 1, 2003.
Under U.S. patent law, utility patents are typically granted for a term of 20 years from the date on which the earliest application was filed, subject to the payment of maintenance fees. For patents claiming priority to applications filed on or after June 8, 1995, the term is generally 20 years from the filing date of the earliest non-provisional application.
In this case, the patent issued on December 2, 2008. The filing date of the parent application is October 1, 2003.
Therefore, the patent term for U.S. Patent No. 7,459,428 is calculated from the earliest priority date, which is October 1, 2003.
Patent Term: 20 years from October 1, 2003.
Expiration Date: October 1, 2023.
As of the present date, this patent has expired.
What is the Prior Art Landscape for Dexmethylphenidate Hydrochloride Formulations?
The prior art landscape for dexmethylphenidate hydrochloride formulations prior to the filing of the patent applications leading to U.S. Patent No. 7,459,428 was characterized by several key aspects:
- Early Formulations: Initial formulations of methylphenidate and its enantiomers were often simple, immediate-release tablets. These formulations could present challenges with rapid absorption, potential for abuse, and dose dumping.
- Enantiomeric Separation: Dexmethylphenidate (d-threo-methylphenidate) emerged as a more potent and potentially better-tolerated enantiomer compared to the racemic mixture of methylphenidate. Patents and publications related to the isolation and purification of dexmethylphenidate existed.
- Extended-Release Technologies: Significant efforts were dedicated to developing extended-release formulations to provide smoother drug delivery, reduce dosing frequency, and mitigate abuse potential. Technologies like osmotic pump systems (e.g., Concerta® for methylphenidate) and matrix-based release systems were prevalent.
- Polymorphism and Stability Issues: The existence of different polymorphic forms (crystalline structures) of pharmaceutical compounds is a known phenomenon. These different forms can exhibit varying physical and chemical properties, including solubility, dissolution rate, bioavailability, and crucially, stability. Before patent No. 7,459,428, there may have been awareness of dexmethylphenidate hydrochloride's potential to exist in different solid states, but specific, highly stable crystalline forms suitable for long-term pharmaceutical formulation may not have been fully characterized or patented.
- Degradation Pathways: Like many amine-containing compounds, dexmethylphenidate hydrochloride could be susceptible to degradation pathways such as oxidation, hydrolysis, and epimerization, especially under adverse storage conditions (e.g., high humidity, temperature fluctuations). The stability of existing formulations would have been a concern for manufacturers and regulators.
The patent application for U.S. Patent No. 7,459,428 specifically aimed to address limitations in existing formulations by identifying and characterizing crystalline forms (Form A and Form B) that demonstrably offered improved stability. This suggests that prior to this patent, the identification and patenting of such highly stabilized forms were not as well-established, providing a basis for novel claims.
What is the Significance of Stabilized Crystalline Forms in Pharmaceutical Development?
Stabilized crystalline forms are critical in pharmaceutical development for several reasons:
- Enhanced Shelf Life: The primary benefit is extended product shelf life. Stable crystalline forms resist degradation pathways (e.g., hydrolysis, oxidation, polymorphic transformation) that can occur during storage, ensuring the drug product remains within its shelf-life specifications for potency and purity. This reduces waste and logistical complexities for manufacturers and pharmacies.
- Consistent Bioavailability: Different crystalline forms can have varying solubilities and dissolution rates. A stable crystalline form ensures that the drug dissolves consistently over time, leading to predictable absorption and consistent bioavailability. This is crucial for therapeutic efficacy, especially for drugs with narrow therapeutic windows like stimulants.
- Improved Manufacturing Process Robustness: A stable crystalline form simplifies manufacturing. It is less prone to unwanted phase transformations during milling, granulation, drying, and compression, leading to a more robust and reproducible manufacturing process. This reduces batch-to-batch variability.
- Reduced Impurity Formation: Degradation of the API leads to the formation of impurities. Stabilized crystalline forms minimize degradation, thereby reducing the formation of potentially harmful impurities. This simplifies regulatory compliance and enhances patient safety.
- Patentability and Market Exclusivity: The identification and patenting of novel, stable crystalline forms (polymorphs) or specific solvates/hydrates provide a distinct basis for patent protection, even if the active pharmaceutical ingredient itself is known. This can extend market exclusivity beyond the expiration of the original API patent.
- Formulation Flexibility: A stable API form provides a more reliable foundation for developing various dosage forms, including immediate-release, extended-release, and combination products.
For dexmethylphenidate hydrochloride, as a CNS stimulant with a defined therapeutic window, the consistency provided by stabilized crystalline forms is particularly important for managing patient symptoms effectively and safely over the duration of treatment.
What is the Impact of Patent Expiration on Generic Competition for Dexmethylphenidate Hydrochloride Products?
The expiration of U.S. Patent No. 7,459,428 on October 1, 2023, has a direct and significant impact on the market for dexmethylphenidate hydrochloride products that are formulated to incorporate the stabilized crystalline forms claimed in this patent.
- Opening for Generic Entry: With the expiration of this patent, generic pharmaceutical manufacturers are now able to develop and market their own versions of dexmethylphenidate hydrochloride products that utilize the stabilized crystalline forms covered by the expired patent. Previously, generic companies were restricted from selling products that infringed on the patent's claims.
- Increased Competition: The entry of generic competitors will increase competition in the market. This typically leads to a significant decrease in drug prices as multiple companies vie for market share.
- Price Reduction: Historically, the introduction of generic alternatives has resulted in substantial price reductions for prescription medications, making them more accessible and affordable to patients. This patent's expiration will likely contribute to a decrease in the cost of dexmethylphenidate hydrochloride treatments reliant on these specific stabilized forms.
- Focus on Bioequivalence: Generic manufacturers will need to demonstrate that their products are bioequivalent to the reference listed drug (RLD) that was protected by the patent. This means proving that their drug is absorbed into the bloodstream at the same rate and to the same extent.
- Potential for Litigation: While the patent has expired, there might be ongoing or past litigation related to infringement that impacted the market entry of some generic products before the patent's expiration. However, post-expiration, the primary hurdle is bioequivalence and regulatory approval.
- Market Share Reallocation: The market share held by the innovator product(s) will likely be reallocated among the generic entrants and the original innovator, who may also introduce their own generic versions or continue to market their branded product.
The expiration of this patent is a key event that facilitates market access for generic dexmethylphenidate hydrochloride products, thereby promoting lower healthcare costs and increased patient access to treatment options.
Key Takeaways
- U.S. Patent No. 7,459,428 protected stabilized crystalline forms (Form A and Form B) of dexmethylphenidate hydrochloride and pharmaceutical compositions containing them.
- These crystalline forms were characterized by specific XRPD and DSC profiles, offering improved stability compared to earlier formulations.
- The patent aimed to address degradation and consistency issues in dexmethylphenidate hydrochloride products.
- The patent term for U.S. Patent No. 7,459,428 expired on October 1, 2023.
- Patent expiration allows generic manufacturers to enter the market with products utilizing these stabilized crystalline forms, leading to increased competition and anticipated price reductions.
Frequently Asked Questions
-
What is the significance of Form A and Form B in the context of this patent?
Form A and Form B are specific crystalline structures of dexmethylphenidate hydrochloride identified and claimed in the patent. They are characterized by distinct X-ray powder diffraction (XRPD) patterns and differential scanning calorimetry (DSC) profiles, and they are asserted to possess enhanced stability compared to other potential crystalline forms or amorphous material.
-
Does the expiration of U.S. Patent No. 7,459,428 mean all dexmethylphenidate hydrochloride products are now off-patent?
No. This patent specifically covered stabilized crystalline forms and their formulations. Other patents may cover the active pharmaceutical ingredient itself (dexmethylphenidate hydrochloride), different polymorphic forms, manufacturing processes, or specific extended-release technologies used in other dexmethylphenidate hydrochloride products. The expiration of this patent primarily affects products that rely on the specific stabilized forms it claimed.
-
How does the stability of crystalline forms impact the efficacy of dexmethylphenidate hydrochloride?
The stability of crystalline forms is crucial for consistent drug efficacy. Stable forms resist degradation, ensuring that the amount of active drug available to the body remains predictable over the product's shelf life. This leads to more consistent therapeutic outcomes in managing ADHD symptoms and reduces the risk of encountering sub-potent or impure medication.
-
What are the typical analytical methods used to confirm the presence of Form A or Form B as claimed in the patent?
The patent specifies X-ray Powder Diffraction (XRPD) and Differential Scanning Calorimetry (DSC) as key methods for characterizing and identifying Form A and Form B. Infrared (IR) spectroscopy is also mentioned as a characteristic analytical technique.
-
What immediate market impact can be expected following the expiration of this patent?
Following the expiration of U.S. Patent No. 7,459,428, generic pharmaceutical companies can now seek approval to market their own dexmethylphenidate hydrochloride products that incorporate the stabilized crystalline forms claimed by the patent. This typically leads to the introduction of generic competition, which historically results in a significant decrease in the price of the medication.
Citations
[1] Shire Pharmaceuticals Ireland Limited. (2008). U.S. Patent No. 7,459,428. Washington, DC: U.S. Patent and Trademark Office.
[2] U.S. Patent Act. (1952). 35 U.S.C.
[3] U.S. Patent Application No. 10/678,247 (filed October 1, 2003).
More… ↓
⤷ Start Trial
|
